Professional Media briefs: November 2013

Share this article:
Vin Tangpricha
Vin Tangpricha

The University of Utah's Ingrid Nygaard and program head for perinatal research and obstetrics of the NIH's National Institute of Child Health and Human ­Development Roberto Romero have been named Editors-in-Chief of the American Journal of Obstetrics and Gynecology. The publication said in a statement that the new editors' agenda includes transforming AJOG to include a robust multimedia platform. The duo replaces EICs Thomas Garite and Moon Kim on January 1.

Elsevier has launched a new open-access publication, the Journal of Clinical and Translational Endocrinology. Editor-in-Chief Vin Tangpricha (pictured) is heading up the operation, which focuses on patient-oriented research that spans disciplines including diabetes, metabolic bone disease and osteoporosis.

An experiment by the journal Science highlighted a pitfall in open-access publishing, which NPR likens to a phishing scam in which questionable journals bypass peer review and publish for fees that can go as high as $3,100. John Bohannan submitted a faked research article in his test garnered a 61% publishing rate for a study that included fundamental method and data errors.

Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro